The race to develop the next generation of weight loss drugs has taken an interesting new turn. In recent research, Eli Lilly’s experimental treatment eloralintide helped people lose a substantial amount of weight—without needing to use the same approach as existing popular medications like Ozempic.

Earlier this month in The Lancet, Eli Lilly researchers and others published the latest phase II trial results of eloralintide. Over a 48-week span, people taking eloralintide lost up to 20% of their baseline body weight, well above the average weight loss experienced by those on placebo. Eloralintide’s early success so far is all the more notable because it isn’t a GLP-1 drug.

A different mechanism

Eloralintide mimics the hormone amylin. Our pancreas naturally releases amylin alongside in

See Full Page